C21 InvestmentsCXXIF +10.72%31 EBITDA Margin % is 15.56% as of Mar. 2026, which is 25% above its 10-year median of 12.48. GuruFocus rates CXXIF with a GF Score™ of 31/100 and a GF Value™ of $0.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 954 Drug Manufacturers companies, C21 Investments ranks better than 52.2% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. C21 Investments's EBITDA for the
three
months ended in Mar. 2026 was $1.16 Mil. C21 Investments's Revenue for the
three
months ended in Mar. 2026 was $7.45 Mil. Therefore, C21 Investments's EBITDA margin for the quarter that ended in Mar. 2026 was 15.56%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
C21 Investments EBITDA Margin % Related Terms
C21 Investments EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for C21 Investments's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where C21 Investments's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments (CXXIF) has a EBITDA Margin % of 15.56% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on C21 Investments and its competitors. This is 25% above median its historical median of 12.48. According to the industry distribution chart, C21 Investments ranks #456 out of 954 companies in the Drug Manufacturers industry, placing it in the top 47.8%.
Is C21 Investments' EBITDA Margin % too high?
C21 Investments' current EBITDA Margin % of 15.56% is 25% above median its 10-year median of 12.48. The Drug Manufacturers industry median EBITDA Margin % is 12.52. C21 Investments' value of 15.56% is 24.3% above this industry median. Based on the distribution chart, C21 Investments ranks #456 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #456 out of 954 companies for EBITDA Margin %. This puts C21 Investments in the upper half of its industry. The industry median EBITDA Margin % is 12.52. C21 Investments' value of 15.56% is 24.3% above this benchmark. While the company's 10-year median is 12.48 vs. the industry median of 12.52, C21 Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current EBITDA Margin % of 15.56% is 24.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current EBITDA Margin % is 15.56%, which is 25% above median its own 10-year median of 12.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.24 — trading 13% below its estimated fair value. The current EBITDA Margin % is 15.56%, which is 25% above median its 10-year median of 12.48 and 24.3% above the Drug Manufacturers industry median of 12.52. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For C21 Investments (CXXIF), the current EBITDA Margin % is 15.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.24 is trading 13% below its estimated GF Value™ of $0.28.
GuruFocus considers C21 Investments to be Modestly Undervalued.
Key valuation signals for CXXIF:
EBITDA Margin %: 15.56% (25% above median its 10-year median of 12.48)
GF Value™: $0.28 vs. price of $0.24 (13% below fair value)
Industry Position: 24.3% above the Drug Manufacturers median (#456 of 954)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
